A Phase II study for the subcutaneous (SC) route of administration of Ruxoprubart (NM8074), designed as a convenient, weekly, self-administered injection in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Latest Information Update: 17 Mar 2026
At a glance
- Drugs Ruxoprubart (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors NovelMed Therapeutics
Most Recent Events
- 17 Mar 2026 New trial record